{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/BDX.AU"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BDX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","market":"AU","secType":"STK","nameCN":"BCAL DIAGNOSTICS LTD","latestPrice":0.09,"timestamp":1745302320000,"preClose":0.095,"halted":0,"volume":98888,"delay":0,"nameEN":"BCAL DIAGNOSTICS LTD","floatShares":202437334,"shares":365967890,"eps":-0.025462,"marketStatus":"Not Yet Opened","change":-0.005,"latestTime":"04-22 16:12:00 AEST","open":0.095,"high":0.095,"low":0.089,"amount":8935,"amplitude":0.063158,"askPrice":0.095,"askSize":50000,"bidPrice":0.09,"bidSize":29944,"shortable":3,"etf":0,"ttmEps":-0.025462,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1745366400000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.095,"openAndCloseTimeList":[[1745280000000,1745301600000]],"volumeRatio":2.147134559126738,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BDX.AU\",,,,,undefined,":{"symbol":"BDX.AU","floatShares":202437334,"roa":"-48.05%","roe":"-104.23%","lyrEps":-0.025993,"volumeRatio":2.147134559126738,"shares":365967890,"dividePrice":0,"high":0.095,"amplitude":0.063158,"preClose":0.095,"low":0.089,"week52Low":0.086,"pbRate":"3.55","psRate":"12.56","week52High":0.185,"institutionHeld":0,"latestPrice":0.09,"committee":-0.250876,"eps":-0.025462,"divideRate":0,"volume":98888,"delay":0,"ttmEps":-0.025462,"open":0.095,"prevYearClose":0.097,"prevWeekClose":0.095,"prevMonthClose":0.102,"prevQuarterClose":0.102,"fiveDayClose":0.089,"twentyDayClose":0.098,"sixtyDayClose":0.093},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BDX.AU\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BDX.AU\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521765148","title":"BCAL Diagnostics' BREASTEST Plus to Generate First Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2521765148","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521765148?lang=en_us&edition=fundamental","pubTime":"2025-03-24 14:39","pubTimestamp":1742798377,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics  said its breast cancer diagnostic product, BREASTEST Plus will generate its first sales revenue this week, according to a Monday Australian bourse filing.The company said it has been granted a diagnostic signature patent by IP Australia providing the diagnostic blood test kit intellectual property protection till 2043.The company's shares jumped 17% on market close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BDX.AU","BCAL"],"gpt_icon":0},{"id":"2521585417","title":"BCAL Diagnostics launches groundbreaking blood test to aid early detection of breast cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2521585417","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521585417?lang=en_us&edition=fundamental","pubTime":"2025-03-24 10:46","pubTimestamp":1742784377,"startTime":"0","endTime":"0","summary":"BCAL Diagnostics  has launched a first-in-class blood test known as BREASTEST plus to address the challenge of high breast density, which can impact standard-of-care breast cancer screening practices.The company designed the lipid test for use alongside traditional mammogram imaging and it has been validated to meet the challenge of high breast density, which affects approximately 50% of Australian women participating in breast cancer screening programs.The new test will be available at Sydney Breast Clinic from 27 March, followed by a planned rollout to select clinical sites nationwide starting with Sydney and Melbourne.“The commercial launch of BREASTEST plus is an incredible milestone for us and for the future of breast cancer screening,” he said.“Anything we can do to detect breast cancer earlier, to rule it in or out, is a vital step forward for women and saving more lives,” he said.Mr Ryan said BCAL also retained exclusive global rights to intellectual property related to the app","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/BCAL-Diagnostics-ASX-BDX-Launches-BREASTEST-plus.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/03/BCAL-Diagnostics-ASX-BDX-Launches-BREASTEST-plus.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/bcal-diagnostics-launches-blood-test-early-detection-breast-cancer/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["XAO.AU","XJO.AU","BCAL","XKO.AU","BDX.AU","BK7067","BK4211"],"gpt_icon":0},{"id":"2520453350","title":"Becton, Dickinson Treats First Breast Revision Patient in GalaFlex Lite Scaffold Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2520453350","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520453350?lang=en_us&edition=fundamental","pubTime":"2025-03-20 19:50","pubTimestamp":1742471442,"startTime":"0","endTime":"0","summary":"Becton, Dickinson  said Thursday that the first patient had been treated in its clinical trial for the use of GalaFlex Lite Scaffold to decrease capsular contracture recurrence during breast revision surgery.Patient enrollment continues for the trial, which will evaluate whether GalaFlex Lite Scaffold will reduce the likelihood of capsular contracture and/or malposition in breast revision surgery, according to the company.Becton, Dickinson said it expects to enroll at least 250 patients across 40 sites for the trial.The company said the trial is intended to advance the product candidate towards premarket approval from the US Food and Drug Administration.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0878866978.SGD","LU0985320562.USD","LU1489326972.SGD","LU0266013472.USD","LU0289961442.SGD","LU0068578508.USD","LU1854104046.USD","LU0985489474.SGD","BDX.AU","LU1150488218.USD","BK7067","BK4588","LU1150488135.SGD","BK4504","LU0511384066.AUD","LU0433182093.SGD","BDX","BK4585","BK4082","LU1894683348.USD","LU1059921491.USD","LU0289739343.SGD","LU1894683264.USD","LU1571399168.USD","LU1854103824.USD","IE00BFXG1179.USD"],"gpt_icon":0},{"id":"2514036576","title":"BRIEF-Bcal Diagnostics Posts HY Net Loss Attributable A$4 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2514036576","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514036576?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:32","pubTimestamp":1740706321,"startTime":"0","endTime":"0","summary":"BRIEF-Bcal Diagnostics Posts HY Net Loss Attributable A$4 MlnFeb 28 (Reuters) - BCAL Diagnostics Ltd BDX.AX:HY NET LOSS ATTRIBUTABLE A$4 MILLIONFurther company coverage: BDX.AX ((Reuters.Briefs@thomsonreuters.com;;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PI29B:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","BDX.AU"],"gpt_icon":0}],"pageSize":4,"totalPage":4,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BDX.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BDX.AU\",market:\"AU\",,,undefined,":[]}}